Abdulkader Rahmo, PhD

Title: Co-founder, President and Chief Scientific Officer
Company: SMSbiotech
Location: Carlsbad, California, United States

Abdulkader Rahmo, PhD, Co-founder, President and Chief Scientific Officer at SMSbiotech, has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in biology.

With more than 15 years of experience to his credit, Dr. Rahmo has excelled as the co-founder, president and chief scientific officer with SMSbiotech since 2020. He was previously active with the aforementioned company as the chief executive officer from 2015 to 2020. Prior to these positions, he served as the chief scientific officer for New Cell Sciences from 2014 to 2015 and both the co-founder and head of the medical biotechnology section for the National Commission for Biotechnology from 2004 to 2013. Dr. Rahmo began his career as the director of a private clinical laboratory with advanced diagnostics at the Center for Bioanalytics in Syria.

Before embarking on his professional path, Dr. Rahmo pursued an education at the Swiss Federal Institute of Technology in Zürich, also known as Eidgenössische Technische Hochschule Zürich, from which he obtained a bachelor’s degree in biological chemistry and biochemistry in 1988. He continued his academic efforts with a Doctor of Philosophy in biochemistry and molecular biology at the University of Southern California in 1994. Following these accomplishments, Dr. Rahmo concluded his studies with postdoctoral coursework at a clinical laboratory in Munich, Germany.

Beyond his responsibilities within the field, Dr. Rahmo has participated in numerous endeavors outside of his professional circles. Having held a number of academic positions, he contributed to  Damascus University as a member of the faculty of medicine in 2001, Western University of Health Sciences as a visiting research scientist in 2013 and the International University for Science & Technology as an associate professor of biochemistry and medical genetics between 2004 and 2015. Dr. Rahmo has also found success with his written works, having authored “Introducing a Novel Human Stem Cell with Exceptional Characteristics: Small, Mobile Stem Cells (SMS)” for the Journal of Life Sciences and Technologies in 2013 as well as “Genotypic Detection of Rifampicin-Resistant M. Tuberculosis Strains of Syrian and Lebanese Patients” in 2012 and ‘Driving the NANO Revolution’ for “Restructuring the World” in 2008.

In light of his exceptional undertakings, Dr. Rahmo has accepted several accolades throughout his career. He has accrued 10 patents within his areas of expertise, including patents for small mobile stem cells between 2018 and 2022. Moreover, he was presented with an Outstanding Leadership Award from Health 2.0 in 2022. Attributing his success to his courage in addition to his decision to become a scientist early in his life,  he has been incredibly proud to help utilize stem calls in the regeneration of lung structures, which has been a game changer in the treatment with chronic obstructive pulmonary disease. In the coming years, Dr. Rahmo hopes to witness his stem cell platform technology be used to treat different diseases while continuing to learn about physiological and biological characteristics to aid in further healing the human body.

Contact Dr. Rahmo:

Leave a Reply